BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14735168)

  • 1. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
    Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
    Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
    Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
    Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
    Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
    Sheikh HY; Valle JW; Waddell T; Palmer K; Wilson G; Sjursen A; Craven O; Swindell R; Saunders MP
    Br J Cancer; 2008 Aug; 99(4):577-83. PubMed ID: 18682717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
    Bennouna J; Perrier H; Paillot B; Priou F; Jacob JH; Hebbar M; Bordenave S; Seitz JF; Cvitkovic F; Dorval E; Malek K; Tonelli D; Douillard JY
    Br J Cancer; 2006 Jan; 94(1):69-73. PubMed ID: 16404362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
    Bajetta E; Di Bartolomeo M; Buzzoni R; Mariani L; Zilembo N; Ferrario E; Lo Vullo S; Aitini E; Isa L; Barone C; Jacobelli S; Recaldin E; Pinotti G; Iop A
    Br J Cancer; 2007 Feb; 96(3):439-44. PubMed ID: 17245343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
    Feliu J; Vicent JM; García-Girón C; Constela M; Fonseca E; Aparicio J; Lomas M; Antón-Aparicio L; Dorta FJ; Gonzalez-Baron M;
    Br J Cancer; 2004 Nov; 91(10):1758-62. PubMed ID: 15505621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
    Cunningham D; Sirohi B; Pluzanska A; Utracka-Hutka B; Zaluski J; Glynne-Jones R; Koralewski P; Bridgewater J; Mainwaring P; Wasan H; Wang JY; Szczylik C; Clingan P; Chan RT; Tabah-Fisch I; Cassidy J
    Ann Oncol; 2009 Feb; 20(2):244-50. PubMed ID: 18854549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
    Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
    Alliot C
    Br J Cancer; 2004 Aug; 91(3):599-600; author reply 599-601. PubMed ID: 15238988
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
    Delord JP; Bennouna J; Artru P; Perrier H; Husseini F; Desseigne F; François E; Faroux R; Smith D; Piedbois P; Naman H; Douillard JY; Bugat R
    Br J Cancer; 2007 Aug; 97(3):297-301. PubMed ID: 17637682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.